Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2019 | Aug. 30, 2019 | |
Document And Entity Information [Abstract] | ||
Entity Registrant Name | Pulse Biosciences, Inc. | |
Entity Filer Category | Accelerated Filer | |
Entity Central Index Key | 0001625101 | |
Amendment Flag | true | |
Document Type | 10-Q/A | |
Document Fiscal Period Focus | Q1 | |
Document Period End Date | Mar. 31, 2019 | |
Document Fiscal Year Focus | 2019 | |
Current Fiscal Year End Date | --12-31 | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | true | |
Entity Small Business | true | |
Entity Common Stock, Shares Outstanding | 20,768,444 | |
Amendment Description | Pulse Biosciences, Inc. (the "Company") is filing this Amendment No. 1 to the Quarterly Report on Form 10-Q/A (this "Amendment") to amend its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2019 filed with the Securities and Exchange Commission (the "SEC") on August 8, 2019 (the "Original Filing"). This Amendment is being filed solely for the purpose of updating Exhibits 31.1 and 31.2. The original exhibits inadvertently omitted certain language regarding management's responsibility for establishing and maintaining internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)). Management has, and at the date of the original filing had, designed internal control over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company's financial statements in accordance with generally accepted accounting principles. Except for the foregoing, the Original Filing remains unchanged. This Amendment does not reflect any events occurring after the filing of the Original Filing, nor does it modify or otherwise update in any way disclosures made in the Original Filing. No revisions are being made to the Company's financial statements or any other disclosure contained in the Original Filing. Accordingly, this Amendment should be read in conjunction with the Company's filings made with the SEC subsequent to the filing of the Original Filing, including any amendment to those filings. |